✦ LIBER ✦

Memantine in Moderately-Severe-to-Severe Alzheimer’s Disease

✍ Scribed by Dr Francesca Clerici, Nicola Vanacore, Antonietta Elia…

Book ID: 120806142
Publisher: Springer International Publishing AG
Year: 2009
Tongue: English
Weight: 184 KB
Volume: 26
Category: Article
ISSN: 1170-229X
DOI: 10.2165/00002512-200926040-00003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost Effectiveness of Memantine in Moder

Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s Disease

✍ Clément François, Harri Sintonen, Raimo Sulkava, Dr Benoît Rive 📂 Article 📅 2004 🏛 Springer International Publishing AG 🌐 English ⚖ 179 KB

Memantine in moderately severe to severe

Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial

✍ Reisberg, Barry; Windscheif, Ursula; Ferris, Steven H.; Hingorani, Vijay N.; Sto 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Memantine in moderate to severe Alzheime

Memantine in moderate to severe Alzheimer’s disease

✍ Andrew Kertesz 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 67 KB

Memantine in Moderate-to-Severe Alzheime

Memantine in Moderate-to-Severe Alzheimer's Disease

✍ Reisberg, Barry; Doody, Rachelle; Stöffler, Albrecht; Schmitt, Frederick; Ferris 📂 Article 📅 2003 🏛 Massachusetts Medical Society 🌐 English ⚖ 121 KB

Memantine in Moderate-to-Severe Alzheime

Memantine in Moderate-to-Severe Alzheimer's Disease

📂 Article 📅 2003 🏛 Massachusetts Medical Society 🌐 English ⚖ 76 KB

Memantine enhances autonomy in moderate

Memantine enhances autonomy in moderate to severe Alzheimer's disease

✍ Benoît Rive; Martine Vercelletto; Florence Delamarre Damier; John Cochran; Cléme 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract ## Background Alzheimer's disease (AD) is the leading cause of dementia and its course renders patients functionally disabled. Memantine is the first drug to demonstrate a clinical benefit in the treatment of patients with moderately‐severe to severe AD. ## Objectives Our objective w